AMS commends funding of MHT menopause medicines 11 Feb 2025

The Australasian Menopause Society has welcomed the recent announcement by the Commonwealth Government in relation to Menopausal Hormone Therapies (MHT), extensive funding for menopause education and an extended menopause consultation time with General Practitioners.

From 1 March 2025, three commonly prescribed MHT products used to effectively treat some of the most common symptoms of the menopause will be available through the Pharmaceutical Benefits Scheme (PBS): Estrogel Pro® (a combination pack of Oestradiol and Progesterone), Oestradiol (Estrogel®) and Progesterone (Prometrium®). MHT is the best treatment for hot flushes.

AMS Board President, Dr Sylvia Rosevear said, ‘The availability of these medicines on the PBS makes these medicines more affordable and provides greater choice, based on need.

MHT discontinuation and shortages Feb 2025

There are a number of MHTs that are currently unavailable. Please note that the TGA has approved some unregistered products under Section 19A and some substitute doses are currently in supply in Australia.

Pharmacists are encouraged to contact suppliers Medsurge Healthcare Pty Ltd on 1300 788 261 for orders of Estramon and Sandoz on 1800 726 369 for orders of Estradiol Transdermal System.